Nektar Therapeutics 提交 8-K（Item 7.01 Reg FD）宣布自 2026-09-08 起进入静默期，直至公布 rezpegaldesleukin 治疗重度斑秃的 Phase 2b REZOLVE-AA 研究 24 周停药随访数据

----- ea0304798-8k_nektar.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
September 8, 2026
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified in Charter)
Delaware
0-24006
94-3134940
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
455 Mission Bay Boulevard South
San Francisco
,
California
94158
(Address of Principal Executive Offices and
Zip Code)
Registrant’s telephone number, including
area code: (
415
)
482-5300
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value
NKTR
Nasdaq
Capital Market
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD.
Nektar Therapeutics (the
“Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data
from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with
severe-to-very-severe alopecia areata. The implementation of the quiet period is consistent with the Company’s prior quiet
periods pertaining to the Phase 2b REZOLVE studies and planned data disclosures.
The information contained in Item 7.01 of this
Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section
and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
1
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
NEKTAR THERAPEUTICS
Date: September 8, 2026
By:
/s/ Elizabeth Zhang
Elizabeth Zhang
Vice President, Legal
2